INFORM HER-2/neu Test: A FISH assay developed to help predict breast cancer recurrence. Approved in December 1997 by FDA to use along with other prognostic tests in lymph node-negative patients with primary, invasive, localized breast tumors. Developed by Oncor Inc., and acquired by Ventana Medical Systems Inc., Tucson, Ariz., in November 1998.
Path Vysion HER-2 DNA Probe Kit: A FISH assay developed specifically for predicting a patients response to doxorubicin. Approved by the FDA in December 1998 as an aid in determining the response of patients with node-positive, stage II breast cancer to cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF). Manufactured by Vysis Inc., Downers Grove, Ill.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |